MoonLake Immunotherapeutics filed a Current Report on Form 8-K on August 10, 2026, disclosing its financial results for the quarter ended June 30, 2026, and announcing positive topline week 16 results from its Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis.

Key Highlights

  • Financial results disclosed: MoonLake Immunotherapeutics released its results of operations and financial condition for the quarter ended June 30, 2026.
  • Phase 3 trial data: The company announced positive topline week 16 results from the Phase 3 IZAR-1 trial of sonelokimab (SLK) in psoriatic arthritis (PSA).
  • Drug candidate: Sonelokimab (SLK) is the investigational therapy evaluated in the IZAR-1 trial.
  • Signed by CFO: The report was signed by Matthias Bodenstedt, Chief Financial Officer, on August 10, 2026.
  • Exchange listing: Class A ordinary shares, par value $0.0001 per share, are listed on The Nasdaq Capital Market under the symbol MLTX.

MoonLake Discloses Q2 2026 Financials and IZAR-1 Phase 3 Topline Results for Sonelokimab

MoonLake Immunotherapeutics (Nasdaq Capital Market: MLTX), incorporated in the Cayman Islands and headquartered in Zug, Switzerland, filed a Current Report on August 10, 2026, covering two items. Under Item 2.02, the company disclosed its results of operations and financial condition for the quarter ended June 30, 2026, with the associated press release furnished as Exhibit 99.1.

Under Item 7.01, the filing reported that on August 10, 2026, the company issued a press release announcing "positive topline week 16 results" from its Phase 3 IZAR-1 trial of sonelokimab (SLK) in psoriatic arthritis (PSA), according to the filing. Both items were furnished to the SEC via the same Exhibit 99.1 press release. The filing specified that the Item 7.01 disclosure and the attached press release "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

The report was signed by Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics, on August 10, 2026. The company indicated it is not an emerging growth company as defined under applicable Securities Act and Exchange Act rules.

What Was Disclosed

MoonLake Immunotherapeutics filed an 8-K on August 10, 2026, furnishing its Q2 2026 financial results and disclosing positive topline week 16 data from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis, both contained in a single press release as Exhibit 99.1.